SG11202005359TA - Phenoxy acids for the treatment of neuromuscular disorders - Google Patents

Phenoxy acids for the treatment of neuromuscular disorders

Info

Publication number
SG11202005359TA
SG11202005359TA SG11202005359TA SG11202005359TA SG11202005359TA SG 11202005359T A SG11202005359T A SG 11202005359TA SG 11202005359T A SG11202005359T A SG 11202005359TA SG 11202005359T A SG11202005359T A SG 11202005359TA SG 11202005359T A SG11202005359T A SG 11202005359TA
Authority
SG
Singapore
Prior art keywords
treatment
neuromuscular disorders
phenoxy acids
phenoxy
acids
Prior art date
Application number
SG11202005359TA
Inventor
Pedersen Thomas Holm
S Knutsen Lars J
Nicholas Kelly
Martin Broch-Lips
Olesen Claus Elsborg
Marc Labelle (Deceased)
Nielsen Ole Bækgaard
Rajesh Kumar
Original Assignee
Nmd Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nmd Pharma As filed Critical Nmd Pharma As
Publication of SG11202005359TA publication Critical patent/SG11202005359TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12Acetic acid esters
    • C07C69/14Acetic acid esters of monohydroxylic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • C07C69/736Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11202005359TA 2017-12-14 2018-12-14 Phenoxy acids for the treatment of neuromuscular disorders SG11202005359TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762598940P 2017-12-14 2017-12-14
EP18151605 2018-01-15
PCT/EP2018/084980 WO2019115777A1 (en) 2017-12-14 2018-12-14 Phenoxy acids for the treatment of neuromuscular disorders

Publications (1)

Publication Number Publication Date
SG11202005359TA true SG11202005359TA (en) 2020-07-29

Family

ID=64661403

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005359TA SG11202005359TA (en) 2017-12-14 2018-12-14 Phenoxy acids for the treatment of neuromuscular disorders

Country Status (11)

Country Link
EP (1) EP3723745B1 (en)
JP (1) JP2021506813A (en)
KR (1) KR20200099146A (en)
CN (1) CN111587109A (en)
AU (1) AU2018382597B2 (en)
CA (1) CA3085226A1 (en)
IL (1) IL274744B2 (en)
MX (1) MX2020005398A (en)
SG (1) SG11202005359TA (en)
TW (1) TWI794369B (en)
WO (1) WO2019115777A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024121130A1 (en) 2022-12-05 2024-06-13 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2024121129A1 (en) * 2022-12-05 2024-06-13 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1586463A (en) 1976-08-02 1981-03-18 Shell Int Research Herbicidal compositions
KR100552133B1 (en) * 2002-06-26 2006-02-14 한국화학연구원 A process for R-Aryloxypropionic acid ester derivatives
SE0301009D0 (en) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
BRPI0907502A2 (en) * 2008-02-04 2019-01-15 Cytokinetics Inc at least one chemical entity, composition, and methods for treating a patient having a condition, for enhancing skeletal muscle function or activity, for enhancing skeletal muscle efficiency, for increasing the time of rapid skeletal muscle fiber fatigue, for sensitize a fast skeletal muscle fiber to produce strength in response to low calcium ion concentrations and to increase skeletal muscle fatigue time
WO2012020567A1 (en) 2010-08-09 2012-02-16 Raqualia Pharma Inc. Acyl piperazine derivatives as ttx-s blockers
BR112017026739A2 (en) * 2015-06-15 2018-08-28 Nmd Pharma Aps compounds for use in the treatment of neuromuscular disorders
US10869858B2 (en) * 2015-10-29 2020-12-22 Tohoku University Therapeutic agent for amyotrophic disorders

Also Published As

Publication number Publication date
EP3723745A1 (en) 2020-10-21
IL274744B (en) 2022-10-01
EP3723745B1 (en) 2024-06-19
KR20200099146A (en) 2020-08-21
MX2020005398A (en) 2020-08-17
AU2018382597A1 (en) 2020-07-02
CN111587109A (en) 2020-08-25
TW201938525A (en) 2019-10-01
JP2021506813A (en) 2021-02-22
WO2019115777A1 (en) 2019-06-20
IL274744B2 (en) 2023-02-01
AU2018382597B2 (en) 2024-04-04
CA3085226A1 (en) 2019-06-20
TWI794369B (en) 2023-03-01
IL274744A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
IL271085A (en) Bacteria for the treatment of disorders
HK1256721A1 (en) Compounds and compositions for the treatment of ocular disorders
IL270752B (en) Pyrrolopyridine-aniline compounds for treatment of dermal disorders
PL3380471T3 (en) Tetrahydro-8h-pyrido[1,2-a]pyrazine-8-ones as comt inhibitors for the treatment of neurodegenerative disorders
ZA202002993B (en) Compounds for the treatment of neuromuscular disorders
IL267818A (en) Methods for the treatment of neurological disorders
EP3606598A4 (en) Method of neural intervention for the treatment of affective neuropsychiatric disorders
GB201612165D0 (en) Combinations for the treatment of type 2 diabetes
IL274744B (en) Phenoxy acids for the treatment of neuromuscular disorders
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
IL288234A (en) Compounds for the treatment of neuromuscular disorders
DK3723746T3 (en) Phenoxy acids for the treatment of neuromuscular disorders
IL269681A (en) New methods for the treatment of multiple sclerosis
HK1250624A1 (en) Methods for the treatment of cardiovascular disorders
PT3724173T (en) Compounds for the treatment of neuromuscular disorders
HRP20181123T1 (en) 3,4-diamino-6-chloropyrazine-2-carboxamide compounds for the treatment of enac mediated diseases
IL254140A0 (en) Compositions and combinations for the treatment of angiogenesis diseases and disorders
AU2016905227A0 (en) Treatment of iron disorders
GB201521542D0 (en) Methods for the treatment of cardiovascular disorders
EP3247396A4 (en) Methods and compositions for the treatment of diseases and disorders
GB201517995D0 (en) Products for treating psychogenic pain disorders
GB201513991D0 (en) Methods for the treatment of cardiovascular disorders
GB201513344D0 (en) Methods for the treatment of Cardiovascular disorders
GB201507109D0 (en) Methods for the treatment of cardiovascular disorders
AU2014902257A0 (en) Treatment of immune disorders 2